Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

NARROW

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only